Anna SF Lok at University of Michigan - Research Interests, Publications & Academic Profile

Anna SF Lok

University of Michigan

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Korean students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Internal Medicine

50%

Pharmacotherapy

30%

Liver Fibrosis

80%

Nafld

60%

Hepatology

50%

Cardiometabolic Health

40%

Antiviral Therapy

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles18

Medically Tailored Meals for Patients With Cirrhosis and Hepatic Encephalopathy: The BRAINFOOD Proof-of-concept Trial

Article Link

Year:

2024

Toward a Functional Cure for Hepatitis B

Article Link

Year:

2024

New perspectives on development of curative strategies for chronic hepatitis B.

Article Link

Year:

2023

Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply

Article Link

Year:

2023

Higher mortality among lean patients with non‐alcoholic fatty liver disease despite fewer metabolic comorbidities

Article Link

Year:

2023

Improving alcohol treatment engagement using integrated behavioral interventions in alcohol-associated liver disease: A randomized pilot trial

Article Link

Year:

2023

Regional changes in intestinal permeability in cirrhosis are associated with mucosal bacteria

Article Link

Year:

2023

Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis

Article Link

Year:

2023

Reply to: “Expert opinion vs. meta-analysis: To be or not to be?”

Article Link

Year:

2023

Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study

Article Link

Year:

2023

Regional changes in intestinal permeability in cirrhosis are associated with mucosal bacteria

Article Link

Year:

2023

Patient Portal Use and Risk of Readmissions in Decompensated Cirrhosis: Retrospective Study

Article Link

Year:

2023

Use of HBV RNA and to predict change in serological status and disease activity in CHB

Article Link

Year:

2023

What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west

Article Link

Year:

2023

Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age

Article Link

Year:

2023

Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion

Article Link

Year:

2022

Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA

Article Link

Year:

2022

Metabolic abnormalities, liver and body fat in American versus Chinese patients with non‐alcoholic fatty liver disease

Article Link

Year:

2022

Collaborators11

Fang Li

Assistant Professor

The University of Texas Health Science Center at Houston

UNITED STATES

Fabien Zoulim

Université Claude Bernard Lyon 1

FRANCE

Vincent Young

Professor

University of Michigan Medical School

UNITED STATES

Christine Bassis

University of Michigan

UNITED STATES

Kelley M Kidwell

Associate Professor

University of Michigan

UNITED STATES

Anne C. Fernandez

University of Michigan

UNITED STATES

Karn Wijarnpreecha

Associate Clinical Professor

University of Arizona College of Medicine

UNITED STATES

Vincent Chen

Assistant Professor

University of Michigan Medical School

UNITED STATES

Mandana Khalili

UNITED STATES

Norah A. Terrault

University of Southern California Keck School of Medicine

UNITED STATES

Gerald Winder

Clinical Associate Professor

University of Michigan

UNITED STATES

How do Korean students reach out?

Meet Kite AI